Predictive Oncology Models Novel Cancer Compounds Using AI

 Predictive Oncology Inc.(POAI), on Tuesday announced that it has successfully developed predictive models for drug discovery using 21 unique compounds sourced from the Natural Products Discovery Core or NPDC at the University of Michigan.

The company leveraged its active machine learning platform to evaluate these novel compounds, targeting prevalent cancer types, including breast, colon, and ovarian cancers.

The predictive models demonstrated promising results, with three compounds showing strong tumor responses across all tumor types tested, surpassing the response of Doxorubicin, a benchmark chemotherapy drug.

These findings support the potential of these compounds as viable drug candidates for cancer treatment.

The partnership with NPDC also showcased the effectiveness of Predictive's platform, which, after measuring only 7% of the possible wet lab experiments, was able to confidently predict outcomes and extend its predictions to cover 73% of all experiments.This process significantly reduces the time and resources needed for laboratory testing, potentially saving up to two years of experimentation.

Predictive Oncology plans to continue investigating these and other compounds from the NPDC's extensive library, further advancing the company's AI-driven drug discovery efforts aimed at improving cancer treatment options.

https://www.rttnews.com/3524143/predictive-oncology-develops-predictive-models-for-novel-cancer-compounds-using-ai-platform.aspx